Medical Versus Surgical Management of Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention
- Conditions
- Myocardial InfarctionMitral Regurgitation
- Interventions
- Procedure: surgical mitral valve repair w/ mitral valve annuloplasty
- Registration Number
- NCT01156441
- Lead Sponsor
- Southern Illinois University
- Brief Summary
The pilot prospective randomized trial is designed to determine the safety and feasibility of enrolling patients to surgically correct residual Mitral Regurgitation (MR) following Percutaneous Coronary Intervention (PCI) for Myocardial Infarction (MI) verses ongoing medical management of MR. The investigators hypothesize that if moderate MR is corrected in this patient subset, the patients will have improved outcomes as measured by decreased number of major adverse cardiac events, including death, congestive heart failure requiring hospitalization, atrial fibrillation, deterioration of New York Heart Association (NYHA) functional status and improved quality of life.
- Detailed Description
Mitral regurgitation (MR) is a frequent complication of myocardial infarction. Ischemic MR portends a poor prognosis on long term follow up. This pilot prospective randomized trial is a safety and feasibility trial to evaluate mitral valve repair versus surgical management in patients with residual MR after primary percutaneous coronary intervention (PCI). Patients will be screened for possible inclusion to identify those that have first MI treated with primary PCI. Patients with moderate MR at 6 or more weeks following first primary PCI will be randomized to continued medical management versus surgical mitral valve repair. Patients with previous or subsequent coronary artery bypass surgery and patients with severe ventricular dysfunction will be excluded. Patients will be followed for one year from the time of randomization. The safety and feasibility data will be used to design a large trial powered to detect a difference in mortality between treatment arms.
Results of this study could lead to a radical change in the treatment paradigm for patients with ischemic MR following PCI for acute MI. In addition, insight gained from this study could advance our understanding of the interrelationship between LV remodeling and MR and shed some light into the mechanism of ventricular function deterioration following MI. Moreover, it may provide a framework for the development of further recommendations with respect to the indications for surgical intervention in this patient population.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Patients who have undergone PCI for first acute MI (index MI) since 7/1/09 at MMC and STJ
- documented moderate mitral regurgitation on follow up echocardiography six or more weeks after PCI procedure
- English speaking
- CABG after PCI for acute MI
- History of previous MI prior to index MI
- History of previous PCI or CABG prior to index PCI
- EF <30 % on the echocardiogram at 6 weeks after PCI for MI
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description surgical mitral valve repair surgical mitral valve repair w/ mitral valve annuloplasty Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree. Mitral valve repair will be performed with mitral valve annuloplasty via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia.
- Primary Outcome Measures
Name Time Method patient survival baseline to 1 year Patient survival will be prospectively documented for all study subjects from recruitment through one year. A stopping rule for the surgical arm is a pre-specified cut-off of 5% based on the method proposed by Kramar and Bascoul-Mollevi in "Early Stopping Rules in Clinical Trials Based on Sequential Monitoring of Serious Adverse Events" \[39\]. A data and safety monitoring board (DSMB) that includes five independent investigators and a statistician has been established to conduct ongoing study review to maintain safety of all participants.
- Secondary Outcome Measures
Name Time Method congestive heart failure requiring hospitalization baseline and 1 year Hospitalization for congestive heart failure will be prospectively documented for all study subjects from recruitment through one year.
mitral regurgitation grade baseline and 1 year Transthoracic echocardiogram will be obtained to assess the presence and or severity of mitral regurgiation.
new atrial fibrillation baseline, 3 months, 6 months and 1 year EKG will be obtained during routine clinical follow up visits and at one year.
NYHA functional class baseline, 3 months, 6 months and 1 year This will be assessed via patient questionnaire using the standard NYHA classification.
Trial Locations
- Locations (1)
Southern Illinois University School of Medicine
🇺🇸Springfield, Illinois, United States